Tumor suppressor p16 methylation in multiple myeloma: Biological and clinical implications

Natalia Gonzalez-Paz, Wee J. Chng, Rebecca F. McClure, Emily Blood, Martin M. Oken, Brian Van Ness, C. David James, Paul J. Kurtin, Kimberly Henderson, Gregory J. Ahmann, Morie Gertz, Martha Lacy, Angela Dispenzieri, Philip R. Greipp, Rafael Fonseca

Research output: Contribution to journalArticle

68 Scopus citations

Abstract

The biological and clinical implications of p16 gene methylation in multiple myeloma (MM) are still unclear despite previous studies. In this comprehensive study, using methylation-specific PCR (MS-PCR), we show that p16 methylation is relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS; n = 17), smoldering multiple myeloma (SMM; n = 40), and MM (n = 522) at a prevalence of 24%, 28%, and 34%, respectively. However, p16 methylation does not appear to affect gene expression level. In a large cohort of patients with long-term follow-up information (n = 439), there was no difference in overall survival between patients with or without p16 methylation. We also found no association between p16 methylation and the main cytogenetic categories, although it was more common among patients with 17p13.1 deletions (p53 locus), a genetic progression event in MM. In addition, p16 methylation has no apparent effect on the cycle because there was also no difference in the plasma cell labeling index (a direct measurement of proliferation) between patients with and without p16 methylation. Our results question a major role for p16 methylation in the oncogenesis of the PC neoplasm, and we now believe p16 methylation may be a marker for overall epigenetic changes associated with disease progression, with no obvious direct biological or clinical consequences.

Original languageEnglish (US)
Pages (from-to)1228-1232
Number of pages5
JournalBlood
Volume109
Issue number3
DOIs
StatePublished - Feb 1 2007

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Tumor suppressor p16 methylation in multiple myeloma: Biological and clinical implications'. Together they form a unique fingerprint.

  • Cite this

    Gonzalez-Paz, N., Chng, W. J., McClure, R. F., Blood, E., Oken, M. M., Van Ness, B., James, C. D., Kurtin, P. J., Henderson, K., Ahmann, G. J., Gertz, M., Lacy, M., Dispenzieri, A., Greipp, P. R., & Fonseca, R. (2007). Tumor suppressor p16 methylation in multiple myeloma: Biological and clinical implications. Blood, 109(3), 1228-1232. https://doi.org/10.1182/blood-2006-05-024661